Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Free Report) has earned a consensus rating of “Moderate Buy” from the five ...

Enanta Pharmaceuticals Inc (ENTA) stock saw a decline, ending the day at $5.75 which represents a decrease of $-0.10 or -1.71% from the prior close of $5.85. The stock opened at $6 and touched a low ...

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule ...

Enanta Pharmaceuticals (ENTA) announced Tuesday it would appeal a recent U.S. federal court ruling that favored Pfizer ...

Enanta Pharmaceuticals (NASDAQ:ENTA – Free Report) had its price objective reduced by HC Wainwright from $27.00 to $18.00 in ...

H.C. Wainwright lowered the firm’s price target on Enanta (ENTA) to $18 from $27 and keeps a Buy rating on the shares. Zelicapavir successfully ...

Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the ...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology ...

Check the time stamp on this data. Updated AI-Generated Signals for Enanta Pharmaceuticals Inc. (ENTA) available here: ENTA.

Enanta Pharmaceuticals plans to appeal a court decision that Pfizer's Covid-19 antiviral drug, Paxlovid, doesn't infringe on its own patents. The U.S. District Court of Massachusetts ruled that Pfizer ...

US-based biotechnology company Enanta Pharmaceuticals has reported positive topline outcomes from its randomised Phase II ...

Enanta Pharmaceuticals (ENTA) announced the United States District Court of Massachusetts has issued a ruling on a summary judgment ...